|  |  |  |  |
| --- | --- | --- | --- |
| **Supplementary Table 2: Factors associated with overall survival of relapsed/refractory MCL patients** | | | |
| **Variable** | **OS in months (95% CI)** | **HR (95% CI)** | **p-value** |
| **Age at relapse (years)** |  |  |  |
| <65 | 55 (35-108) | Reference | **0.0417** |
| ≥65 | 22 (10-86) | 2.66 (1.04-6.82) |  |
| **Sex** |  |  |  |
| Female | 52 (22-86) | Reference | 0.810 |
| Male | 51 (1-51) | 0.88 (0.32-2.42) |  |
| **sMIPI at diagnosis** |  |  |  |
| Low | 55 (13-106) | Reference | 0.9253 |
| Intermediate | 52 (12-86) | 1.19 (0.46-3.13) |  |
| High | 27 (1-27) | 1.02 (0.31-3.35) |  |
| **Early relapse/progression\*** |  |  |  |
| No | 55 (35-108) | Reference | **0.0005** |
| Yes | 13 (8-37) | 10.69 (2.8-40.8) |  |
| **Ever used novel therapy** |  |  |  |
| No | 35 (10-37) | Reference | 0.4054 |
| Yes | 55 (27-106) | 0.67 (0.26-1.74) |  |
| **Ever used BTK inhibitor** |  |  |  |
| No | 51 (14- 106) | Reference | 0.5299 |
| Yes | 55 (13-86) | 0.74 (0.29-1.89) |  |
| **HSCT at initial treatment** |  |  |  |
| No | 51 (22-86) | Reference | 0.2707 |
| Yes | 52 (25-52) | 0.53 (0.17-1.65) |  |